$CORT

+Initiations 6/27: $ACM $AXTI $BLBX $CORT $DRI $ENOV $GROV $IFF $LQDT $ML $RPM $SIGI $TXRH . -Initiations 6/27: $ALB $BPMC $CE $EAT $LYB $ORCL

Unusually active option classes on open December 16th $BEKE $CORT $KGC $VRM $UPS $T $NVAX $SHOP $BKKT $NVDA

$CORT green

stabbed some ss on $CORT here

wow $CORT picking up steam

$CORT 20.50's will be interesting

Possible first red days: $GOGO, $SHLL, $CORT, $FEAC, $FMCI

congrats to $CORT ss

taking $CORT long here 19.70

wow $CORT today

$CORT 88M Float!? hmmm

whats up with $CORT ? not seeing anything on it

long CORT for rip into close

I wouldn’t even short CORT here

shorting weakness on CORT is how it traps shorts

CORT had big calls coming in at 19, 20 level, majority institutionally owned, very high float yet up 100%... so that was my confirmation not to enter , or if i did, be supremely nimble

anyone see $CORT

whats the news on $CORT anyway

glad I covered most on $CORT

there goes CORT

covered 1/2 CORT low 18s

Cov some $cort

only got 500 shares left in $CORT

dont understand CORT at all

Largest Call/Put Ratio: $CORT

uoa $CORT 18C Sept

$ASND At $5.5B EV ( $1B in cash) this is compelling risk / reward with big upside from these levels imo. Had to free some cash. Sold out $CORT due to not as high conviction (Teva lawsuit bothers me lol) plus profit is profit. Summary: -Derisked gHD (growth hormone deficiency) best in class ONCE-WEEKLY therapy. Standard of care currenttly are daily injections of hGH. - Based on P2 data de-risked to great extent HP (hypoparathyroidism) PTH compound. Potentially superior over Natpara that's currently recalled by FDA. Patients desperately need new therapies here. > $1B on peak rev potential. raps.org/news-and-articles/... - Transcon CNP in P2 trial for Achondroplasia. Currently there are NO any FDA-approved treatments to address this most common type of dwarfism. - Move into Oncology therapeutic area based on Vision 3x3 strategic roadmap. 3rd therapeutic area for TransCon TBD